184 related articles for article (PubMed ID: 2523194)
1. Adverse effects related to thionamide drugs and their dose regimen.
Werner MC; Romaldini JH; Bromberg N; Werner RS; Farah CS
Am J Med Sci; 1989 Apr; 297(4):216-9. PubMed ID: 2523194
[TBL] [Abstract][Full Text] [Related]
2. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
[TBL] [Abstract][Full Text] [Related]
3. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
4. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
Kubota S
Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
7. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism.
Momotani N; Noh JY; Ishikawa N; Ito K
J Clin Endocrinol Metab; 1997 Nov; 82(11):3633-6. PubMed ID: 9360518
[TBL] [Abstract][Full Text] [Related]
8. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease.
Tsuboi K; Ueshiba H; Shimojo M; Ishikawa M; Watanabe N; Nagasawa K; Yuasa R; Yoshino G
Endocr J; 2007 Feb; 54(1):39-43. PubMed ID: 17053291
[TBL] [Abstract][Full Text] [Related]
9. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome.
Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y
J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520
[TBL] [Abstract][Full Text] [Related]
10. The propylthiouracil dilemma.
Glinoer D; Cooper DS
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):402-7. PubMed ID: 22820213
[TBL] [Abstract][Full Text] [Related]
11. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China.
Yang J; Li LF; Xu Q; Zhang J; Weng WW; Zhu YJ; Dong MJ
Thyroid; 2015 Mar; 25(3):278-83. PubMed ID: 25384184
[TBL] [Abstract][Full Text] [Related]
12. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism.
Okamura K; Ikenoue H; Shiroozu A; Sato K; Yoshinari M; Fujishima M
J Clin Endocrinol Metab; 1987 Oct; 65(4):719-23. PubMed ID: 3654917
[TBL] [Abstract][Full Text] [Related]
13. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
[TBL] [Abstract][Full Text] [Related]
14. Toxicities associated with 1-month treatment with propylthiouracil (PTU) and methimazole (MMI) in male rats.
Nambiar PR; Palanisamy GS; Okerberg C; Wolford A; Walters K; Buckbinder L; Reagan WJ
Toxicol Pathol; 2014 Aug; 42(6):970-83. PubMed ID: 24067673
[TBL] [Abstract][Full Text] [Related]
15. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
[TBL] [Abstract][Full Text] [Related]
16. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.
Wang MT; Lee WJ; Huang TY; Chu CL; Hsieh CH
Br J Clin Pharmacol; 2014 Sep; 78(3):619-29. PubMed ID: 25279406
[TBL] [Abstract][Full Text] [Related]
17. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
18. Safety of antithyroid drugs in pregnancy: update and therapy implications.
Francis T; Francis N; Lazarus JH; Okosieme OE
Expert Opin Drug Saf; 2020 May; 19(5):565-576. PubMed ID: 32223355
[No Abstract] [Full Text] [Related]
19. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose.
Cooper DS; Goldminz D; Levin AA; Ladenson PW; Daniels GH; Molitch ME; Ridgway EC
Ann Intern Med; 1983 Jan; 98(1):26-9. PubMed ID: 6687345
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
Kobayashi S; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Ohye H; Suzuki M; Yoshihara A; Iwaku K; Sugino K; Ito K
Thyroid; 2014 May; 24(5):796-801. PubMed ID: 24341564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
